The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...
This adjustment reflects the discontinuation of the belrestotug program, following disappointing trial results. Despite these setbacks, iTeos continues its research efforts, with ongoing studies such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback